Opinion|Videos|October 21, 2024
Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Key Takeaways
- Disparities in clinical guidelines and access to therapies can lead to varied treatment outcomes in uro-oncology.
- Patient adherence is influenced by treatment complexity, financial constraints, and healthcare professional support.
Panelists discuss how the differences in routes of administration, durations of therapy, and control arms among PD1/PD-L1 inhibitors in trials may impact patient care, resource utilization, and treatment adherence, highlighting key insights from recent Uro Oncology presentations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Explain how these differences may impact patient care, resource use, and adherence. [Uro Oncology presentation by Psutka]
Bedke 2023
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Sarah Azari, MD, on early sexual health education for women with bladder cancer
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5